Stallergenes Greer

Executive Summary

Stallergenes Greer is a global leader in allergen immunotherapy (AIT), with over a century of combined expertise and the world's largest manufacturing capacity for allergens. The company offers a comprehensive portfolio of AIT products for respiratory, venom, and food allergies, positioning it as a key player in the growing allergy treatment market. Its proprietary manufacturing processes and extensive allergen library provide a competitive moat. As a private company, Stallergenes Greer benefits from long-term strategic focus without the pressure of quarterly earnings. The global AIT market is expanding due to rising allergy prevalence and increased awareness of disease-modifying therapies. While competition exists from other AIT products, the company's established market presence, diversified pipeline, and large-scale manufacturing capabilities underpin its growth. However, limited public disclosure makes it challenging to assess near-term financial performance.

Upcoming Catalysts (preview)

• TBDFDA approval or clinical trial readout for a food allergy AIT product60% success
• TBDExpansion into emerging markets via partnerships or local manufacturing65% success
• TBDLaunch of a next-generation sublingual immunotherapy tablet for respiratory allergies60% success